4552 — JCR Pharmaceuticals Co Balance Sheet
0.000.00%
- ¥78bn
 - ¥105bn
 - ¥33bn
 
- 24
 - 35
 - 48
 - 24
 
Annual balance sheet for JCR Pharmaceuticals Co, fiscal year end - March 31st, JPY millions except per share, conversion factor applied.
2021 March 31st  | 2022 March 31st  | 2023 March 31st  | 2024 March 31st  | 2025 March 31st  | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — | 
| Source: | Yuho | Yuho | Yuho | Yuho | Yuho | 
| Standards: | JAS | JAS | JAS | JAS | JAS | 
| Status: | Final | Final | Final | Final | Final | 
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 26,260 | 30,977 | 13,278 | 18,756 | 13,196 | 
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 8,183 | 15,585 | 11,137 | 14,934 | 12,236 | 
| Total Inventory | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 48,545 | 62,188 | 47,802 | 57,581 | 51,056 | 
| Net Property, Plant And Equipment | 17,172 | 26,782 | 32,681 | 30,040 | 37,410 | 
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 73,784 | 97,134 | 94,937 | 102,226 | 104,855 | 
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 29,028 | 42,054 | 35,762 | 30,135 | 43,988 | 
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 35,401 | 46,250 | 42,775 | 46,048 | 57,812 | 
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Unrealized Gain / Loss | |||||
| Other Equity | |||||
| Total Equity | 38,383 | 50,884 | 52,162 | 56,178 | 47,043 | 
| Total Liabilities & Shareholders' Equity | 73,784 | 97,134 | 94,937 | 102,226 | 104,855 | 
| Total Common Shares Outstanding |